Healthcare / Medical Instruments & SuppliesUpdated 2026-05-10 22:07 UTC

RGNT stock hub

Regentis Biomaterials Ltd. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RGNTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

11.5M

NYSEAMERICAN

Market data

Live price

Current market quote for this ticker.

Current price

RGNT

In the news

Latest news · RGNT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-178.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RGNT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

138

Groups with data

Currency

USD

Showing 138 of 138 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001912966
Company name	Regentis Biomaterials Ltd.
Country	Israel
Country code	US
Cusip	001219096
Employees	7
Enterprise value	$5.3M
Exchange	NYSEAMERICAN
Financial currency	USD
First seen	2026-05-09
Industry	Medical Instruments & Supplies
IPO Date	2025-12-04
Isin	IL0012190968
Last refreshed	2026-05-10
Market cap	$11.5M
Market cap category	Nano-Cap
Price	$2.22
Price currency	USD
Sector	Healthcare
Sic	3842
Symbol	RGNT
Tags	pharmaceuticals
Website	https://www.regentis.co.il

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-119.08%
P/B ratio	2.42x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-13.7M
Net Income Growth Years	0%
Profit Per Employee	$-2M
ROA	-107.5
Roa5y	-28.07
ROCE	-146.9
ROIC	-178.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$7.6M
Cash	$7.4M
Current Assets	$7.6M
Current Liabilities	$2.9M
Debt	$1.2M
Debt Equity	$0.25
Equity	$4.7M
Interest Coverage	-88.2
Liabilities	$2.9M
Long Term Assets	$0
Long Term Liabilities	$0
Net Cash	$6.2M
Net Cash By Market Cap	$53.76
Net Debt Equity	$-1.3
Tangible Book Value	$4.7M
Tangible Book Value Per Share	$0.92

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.65
Net Working Capital	$-1.4M
Quick ratio	2.65
Working Capital	$4.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-249.42%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	3.11
All Time High	8.35
All Time High Change	-73.41%
All Time High Date	2026-01-16
All Time Low	2.01
All Time Low Change	10.45%
All Time Low Date	2026-05-08
ATR	0.22
Beta1y	0.97
Ch YTD	-67.06
High	2.35
High52	8.35
High52 Date	2026-01-16
High52ch	-73.41%
Low	2.01
Low52	2.01
Low52 Date	2026-05-08
Low52ch	10.45%
Ma50ch	-28.69%
Premarket Change Percent	-1.75
Premarket Price	$2.24
Premarket Volume	1,328
RSI	20.37
RSI Monthly	0
RSI Weekly	16.54
Sharpe ratio	-3.61x
Sortino ratio	-4.07
Total Return	-249.42%
Tr YTD	-67.06
Tr1m	-28.39%
Tr1w	-22.65%
Tr3m	-54.04%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-7M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,697,634%
Float Percent	52.08%
Net Borrowing	300,000
Shares Insiders	2.48%
Shares Institutions	10.78%
Shares Out	5,179,378
Shares Qo Q	498.83%
Shares Yo Y	249.42%
Short Float	0.48%
Short Ratio	2.66
Short Shares	0.25

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	8,307.6x
Bv Per Share	0.92
Ch1m	-28.39
Ch1w	-22.65
Ch3m	-54.04
Change	-2.63%
Change From Open	0.82
Close	2.28
Days Gap	-3.42
Dollar Volume	27,896.5
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-7M
EPS	$-24.16
F Score	2
Financing CF	8,524,000
Fiscal Year End	December
Founded	2,004
Ipr	-72.25
Iprfo	-70
Is Primary Listing	1
Is Spac	No
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-02-24
Ma20	2.86
Ma20ch	-22.49%
Net CF	7,149,000
Next Earnings Date	2026-05-22
Open	2.2
Optionable	No
Position In Range	61.76
Pre Close	2.28
Price Date	2026-05-08
Ptbv Ratio	2.42
Relative Volume	1.51x
Share Based Comp	7,042,000
Volume	12,566

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RGNT pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns RGNT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.8%

Float: +52.1% of shares outstanding

Insider ownership

+2.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RGNT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

20.4

Below 30: short-term oversold

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-3.61

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RGNT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RGNT stock rating?

Regentis Biomaterials Ltd. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RGNT analysis?

The full report lives at /stocks/RGNT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RGNT?

The latest report frames RGNT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RGNT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.